RxDoctor Payments Data

Mary Irene Beatrice Feria, MD

Endocrinology, Diabetes & Metabolism · Kalispell, MTNPI 1447244454

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.4% of the total across 18 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 9 manufacturers, the largest accounting for just 22.1% — the pattern of someone who eats at a lot of different presentations.

$303in general payments, 2019–2025

Across 18 payments — averaging $16.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$67
  • Boehringer Ingelheim$48
  • Tandem Diabetes Care, Inc.$46
  • Novo Nordisk$43
  • Amgen$39
  • Sequel Med Tech, LLC$21
  • plus $39 from 3 others

What the payments were for

  • Food & beverage$28995%
  • Education$145%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few endocrinology, diabetes & metabolism providers in Montanato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$74,749
Medicare patients
260
Services billed
1,150

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide290$301,759
JardianceEmpagliflozin135$153,739
Tresiba Flextouch U-200Insulin Degludec50$78,784
RybelsusSemaglutide46$68,798
TrulicityDulaglutide52$61,308
Tresiba Flextouch U-100Insulin Degludec76$54,859
MounjaroTirzepatide25$44,601
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog20$38,621
Humalog Kwikpen U-200Insulin Lispro20$31,234
Novolog FlexpenInsulin Aspart76$23,929
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog27$18,884
HumalogInsulin Lispro55$18,192
JanuviaSitagliptin Phosphate25$16,988
Humalog Kwikpen U-100Insulin Lispro56$16,728
Fiasp FlextouchInsulin Aspart (Niacinamide)24$15,364

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$43$374,565351 claims
Boehringer IngelheimJardiance$48$153,739135 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog, Baqsimi, Insulin Lispro$67$130,761156 claims
MerckJanuvia$12$16,98825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology, diabetes & metabolism providers in Montanaon file to place this against a meaningful peer group, so we don't.

Other endocrinology, diabetes & metabolism in Kalispell

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →